Manu Asthana 1 , Sushil Kumar Sahu 1 , Amit Kumar 1 , Suchitra Mohanty 1 , Sudipta Chakrabarti 1 , Piyanki Das 2 , Nabanita Roy Chattopadhya 2 , Koustav Chatterjee 2 , Shivaram Prasad Singh 3 , Shanmugam Rajasubramaniam 4 , Tathagata Choudhuri 2 Show Affiliations »
Abstract
BACKGROUND: Interleukin-28B (IL28B) locus on a human chromosomal region mapped to 19q13 execute immune defense against viruses. During Hepatitis C Virus (HCV) infection the IL28B has a promising role in deciding the consequence of infection for spontaneous clearance of viruses or causing chronic liver infection. Treatment of chronic hepatitis C includes use of direct acting antivirals, Pegylated-Interferon (PEG-IFN) and Ribavirin (RBV) therapy. Also, interferon free regimens are suggested to be useful in resistant patients. Numerous reports including Genome-Wide Association Studies (GWAS), comprehensive meta-analysis and independent case-control studies in different population have revealed the association between certain Il-28B polymorphisms and response to the PEGIFN- RBV therapy in patients infected with HCV. METHOD: We searched all peer-reviewed relevant and recent literature manually for the present review. CONCLUSION: The GWAS studies have revealed an important role of IL28B in HCV infection, which was supported by many independent studies and meta-analysis by different groups in different ethnicities. IL28B genotyping may be use as predictors of response for IFN-based therapy and personalized treatment of hepatitis C patient. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
BACKGROUND: Interleukin-28B (IL28B ) locus on a human chromosomal region mapped to 19q13 execute immune defense against viruses. During Hepatitis C Virus (HCV) infection the IL28B has a promising role in deciding the consequence of infection for spontaneous clearance of viruses or causing chronic liver infection . Treatment of chronic hepatitis C includes use of direct acting antivirals, Pegylated-Interferon (PEG-IFN ) and Ribavirin (RBV ) therapy. Also, interferon free regimens are suggested to be useful in resistant patients . Numerous reports including Genome-Wide Association Studies (GWAS), comprehensive meta-analysis and independent case-control studies in different population have revealed the association between certain Il-28B polymorphisms and response to the PEGIFN- RBV therapy in patients infected with HCV . METHOD: We searched all peer-reviewed relevant and recent literature manually for the present review. CONCLUSION: The GWAS studies have revealed an important role of IL28B in HCV infection , which was supported by many independent studies and meta-analysis by different groups in different ethnicities. IL28B genotyping may be use as predictors of response for IFN-based therapy and personalized treatment of hepatitis C patient . Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Entities: Chemical
Disease
Gene
Species
Keywords:
GWAS; HCV; IL28B; pegylated-interferon; ribavirin therapy; sustained virological response.
Mesh： See more »
Substances： See more »
Year: 2018
PMID： 29380700 DOI： 10.2174/1389200219666180129115359
Source DB: PubMed Journal: Curr Drug Metab ISSN： 1389-2002 Impact factor: 3.731